Advancing Towards Regulatory Approval for Severe Hypertriglyceridemia TreatmentRelated Stocks: ARWR,...
PASADENA, Calif.--(BUSINESS WIRE)--Jun 23, 2025--...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has received an average recommendati...
Rhumbline Advisers cut its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) b...
Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) have been assigned a conse...